LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns positive
Q1 FY2026 Accumulated OCI was $208K, compared with -$0 a year earlier.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +1464788732394466.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 168K USD
- Year-over-year change
- +51.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 168K | +51.4% |
| FY2024 | 2024-12-31 | 111K | -59.5% |
| FY2023 | 2023-12-31 | 274K | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 Accumulated OCI of $208K is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +1464788732394466.3% is the highest of 9, against a peer median of -141.4%.
- Accumulated OCI amounts to 0.1% of total assets for LBRX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.92M | +173.2% | — | 1.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $208K | +1464788732394466.3% | — | 0.1% |
| Mar 2026 | $13K | -7.1% | — | 0.0% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | +100.0% | — | 0.0% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$505K | -431.6% | — | 0.1% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$829K | -182.8% | +20.1% | 0.1% |
| Mar 2026 | -$883K | -1138.8% | — | 0.2% | |
| Jun 2026 | -$1.97M | -309.7% | — | 0.2% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $0 | -141.4% | +20.1% | 0.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.